Pegnivacogin

Summary

Pegnivacogin (CHEMBL2107870) is a phase-3 clinical-stage unknown; indicated across 2 conditions including coronary artery disorder and acute coronary syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107870
Name	Pegnivacogin
Type	Unknown
Max phase	3

Also known as: Pegnivacogin, Pegnivacogina, RB-006, RB006, REG-1, REG1, PEGNIVACOGIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coronary artery disorder	3	MONDO:0005010	EFO:0001645
acute coronary syndrome	2	MONDO:0005542	EFO:0005672

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01848106	PHASE3	TERMINATED	A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
NCT00715455	PHASE2	COMPLETED	Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
NCT00932100	PHASE2	COMPLETED	A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome
NCT00113997	PHASE1	COMPLETED	Safety and Dosing Evaluation of REG1 Anticoagulation System
NCT01872572	PHASE1	COMPLETED	Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).